WO2003051281A3 - Composition and method to treat viral bacterial and parasitic infections and infestations - Google Patents

Composition and method to treat viral bacterial and parasitic infections and infestations Download PDF

Info

Publication number
WO2003051281A3
WO2003051281A3 PCT/US2002/033060 US0233060W WO03051281A3 WO 2003051281 A3 WO2003051281 A3 WO 2003051281A3 US 0233060 W US0233060 W US 0233060W WO 03051281 A3 WO03051281 A3 WO 03051281A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
infestations
animal
lysozyme
parasitic infections
Prior art date
Application number
PCT/US2002/033060
Other languages
French (fr)
Other versions
WO2003051281A2 (en
Inventor
Stephen E Bachman
Michael E Hubbert
Original Assignee
Ganado Res L L C
Stephen E Bachman
Michael E Hubbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganado Res L L C, Stephen E Bachman, Michael E Hubbert filed Critical Ganado Res L L C
Priority to AU2002365083A priority Critical patent/AU2002365083A1/en
Publication of WO2003051281A2 publication Critical patent/WO2003051281A2/en
Publication of WO2003051281A3 publication Critical patent/WO2003051281A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Abstract

A composition for nasal administration to animals, including humans. Applicants' composition includes lysozyme in combination with zinc. In certain embodiments, the composition further includes one or more anthelmentic compounds. A method to treat animals, including humans, having a pulmonary bacterial infection by delivering a therapeutically effective amount of lysozyme to the animal's nasal pharynx. A method to treat animals, including humans, having a viral infection by delivering a therapeutically effective amount of zinc to the animal's nasal pharynx. In certain embodiments, the method further includes delivering lysozyme to the animal's nasal pharynx.
PCT/US2002/033060 2001-10-17 2002-10-17 Composition and method to treat viral bacterial and parasitic infections and infestations WO2003051281A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002365083A AU2002365083A1 (en) 2001-10-17 2002-10-17 Composition and method to treat viral bacterial and parasitic infections and infestations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32993701P 2001-10-17 2001-10-17
US60/329,937 2001-10-17

Publications (2)

Publication Number Publication Date
WO2003051281A2 WO2003051281A2 (en) 2003-06-26
WO2003051281A3 true WO2003051281A3 (en) 2003-12-18

Family

ID=23287659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033060 WO2003051281A2 (en) 2001-10-17 2002-10-17 Composition and method to treat viral bacterial and parasitic infections and infestations

Country Status (2)

Country Link
AU (1) AU2002365083A1 (en)
WO (1) WO2003051281A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1322045C (en) * 2005-07-27 2007-06-20 丁宏广 Bactericidal enzyme agglomerate, bactericidal enzyme polymer monofilament and its preparing process and uses
US8445024B2 (en) 2005-10-25 2013-05-21 Evonik Degussa Gmbh Preparations containing hyperbranched polymers
DE102005051366A1 (en) * 2005-10-25 2007-04-26 Degussa Gmbh Drug delivery systems
IT1391170B1 (en) * 2008-08-07 2011-11-18 D M G Italia S R L INTRA-NASAL TOPIC COMPOSITION USABLE IN CASE OF NASAL OBSTRUCTION
US20130028882A1 (en) * 2011-07-07 2013-01-31 Humanitas Technology, LLC Antiviral compositions and methods of their use
KR20180120204A (en) 2016-02-25 2018-11-05 어플라이드 바이올로지컬 래버러토리즈 인코포레이티드 Compositions and methods for protecting airborne pathogens and stimulants
US20170360815A1 (en) * 2016-02-25 2017-12-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
CN115361944A (en) * 2020-01-10 2022-11-18 均衡生物制药私人有限责任公司 Treatment of neurological disorders with avermectins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5428006A (en) * 1990-05-10 1995-06-27 Bechgaard International Research And Development A/S Method of administering a biologically active substance
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5428006A (en) * 1990-05-10 1995-06-27 Bechgaard International Research And Development A/S Method of administering a biologically active substance
US5693608A (en) * 1990-05-10 1997-12-02 Bechgaard International Research And Development A/S Method of administering a biologically active substance
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same

Also Published As

Publication number Publication date
WO2003051281A2 (en) 2003-06-26
AU2002365083A1 (en) 2003-06-30
AU2002365083A8 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
WO2002002128A3 (en) Oral compositions comprising antimicrobial agents
EP1247456A3 (en) Palatable pharmaceutical compositions for companion animals
DE69734215D1 (en) Compounds with growth hormone-releasing properties
JP2009526751A5 (en)
WO2001045679A3 (en) Use of chemotherapeutic agents for topical treatment
IT1318430B1 (en) DEVICE FOR PASSIVE HUMIDIFICATION OF TRACHEOSTOMIZED OR INTUBATED PATIENTS.
WO2002053101A3 (en) Method for treating fibrotic diseases or other indications
HRP20080492T3 (en) Phenyl-carboxamide compounds useful for treating pain
WO1999052515A3 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections
CA2414576A1 (en) Promoting whole body health
WO2003004098A8 (en) Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
WO2003051281A3 (en) Composition and method to treat viral bacterial and parasitic infections and infestations
WO2003059246A3 (en) Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
WO2004089355A8 (en) Compositions for treating microbial and parasitic infections in cattle and other animals
WO2000037064A3 (en) Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
WO2000066094A3 (en) Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents
WO2002020619A3 (en) HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
WO2004039822A3 (en) 4’’ - modified erythromycin derivatives
PL345452A1 (en) Chemotaxis-inhibiting protein of staphylococcus
EP1238669A3 (en) Neutrophil function inhibitors which contain glucosamine
WO2000016757A8 (en) Use of organophosphorous compounds for producing medicaments for the therapeutic and prophylactic treatment of infections or as a fungicide, bactericide or herbicide for plants
WO1999012552A8 (en) 9a-AZALIDES AS VETERINARY ANTIMICROBIAL AGENTS
WO2008033477A3 (en) Antimicrobial activity in variants of lacritin
WO2007058639A3 (en) Antibacterial agents
WO2003024996A3 (en) Antibacterial macrocycles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP